Efficacy and safety of probiotics for irritable bowel syndrome : a systematic review
10.3760/cma.j.cn115822-20240414-00063
- VernacularTitle:益生菌对肠易激综合征的干预效果和安全性评价的系统综述
- Author:
Xiaoyang ZHAO
1
;
Xinyue HU
;
Aoxing ZHAO
;
Xiyi ZHAO
;
Zhiyi MAO
;
Chang LU
;
Yuchen LI
;
Xi SHEN
Author Information
1. 四川大学华西公共卫生学院营养与食品卫生学系，成都 610041
- Publication Type:Journal Article
- Keywords:
Irritable bowel syndrome;
Probiotics;
Intestinal flora;
Randomized controlled trial
- From:
Chinese Journal of Clinical Nutrition
2025;33(1):72-80
- CountryChina
- Language:Chinese
-
Abstract:
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder and its symptoms are subject to the composition of the gut microbiota. However, it is not yet clear how probiotics relieve IBS, and there is no well-acknowledged standards concerning the clinical application of probiotics. This systematic review was conducted on the literature published from January 2020 to December 2023 and included 12 randomized controlled trials on probiotics in the treatment of IBS. Compared with placebo, the probiotic preparations improved the overall efficacy in IBS patients and was also well tolerated, suggesting the potential of probiotics in IBS management. Nevertheless, different probiotic strains, dosages, combinations, and dosing schedules may affect the outcomes. In the future, large-scale, multi-center, long-term follow-up studies are still needed to clarify the effective strains and methods of use and to promote the use of probiotics in the treatment of IBS.
